Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Journal article
Baigent C. and Sádaba R., (2023), Eur Heart J
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Journal article
Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
Journal article
Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Journal article
Zhou J. et al, (2023), Pharmacoeconomics
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Journal article
Chapman D. et al, (2023), Kidney Int
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Journal article
Humbert M. et al, (2023), European Respiratory Journal, 61
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Journal article
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Journal article
Staplin N. et al, (2022), Hypertension, 79, 2671 - 2681
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
Journal article
Gaziano L. et al, (2022), Circulation
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Journal article
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial.
Journal article
Wang X. et al, (2022), Eur Heart J Digit Health, 3, 426 - 436
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Journal article
Pitcher A. et al, (2022), Lancet
CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.
Journal article
Kotecha D. et al, (2022), Lancet Digit Health
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
Focused cardiac ultrasound to guide the diagnosis of heart failure in pregnant women in India.
Journal article
Alsharqi M. et al, (2022), J Am Soc Echocardiogr
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials